A Collaborative Approach for "ReSeq-ing" Mycobacterium tuberculosis Drug Resistance: Convergence for Drug and Diagnostic Developers

EBioMedicine

Volumn 2, Issue 10, 2015, Pages 1262-1265

  Schito, Marco ^a   Dolinger, David L ^b  

^a CRITICAL PATH INSTITUTE   (United States)

^b FIND   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; DELAMANID; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; LINEZOLID; MOXIFLOXACIN; PRETOMANID; PYRAZINAMIDE; TUBERCULOSTATIC AGENT;

ANTIBIOTIC RESISTANCE; BIOINFORMATICS; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; FACTUAL DATABASE; GENE MUTATION; GENE SEQUENCE; GENETIC RESISTANCE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NOTE; PRIORITY JOURNAL; RELATIONAL SEQUENCING TUBERCULOSIS DATA PLATFORM; RESISTANCE ASSOCIATED MUTATION; SINGLE NUCLEOTIDE POLYMORPHISM; TUBERCULOSIS; BIOLOGY; COMBINATION DRUG THERAPY; COOPERATION; DNA SEQUENCE; DRUG EFFECTS; GENETICS; MICROBIOLOGY; PROCEDURES; TUBERCULOSIS, MULTIDRUG-RESISTANT;

ANTITUBERCULAR AGENTS; COMPUTATIONAL BIOLOGY; COOPERATIVE BEHAVIOR; DRUG THERAPY, COMBINATION; HUMANS; MYCOBACTERIUM TUBERCULOSIS; SEQUENCE ANALYSIS, DNA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84949844093     PISSN: None     EISSN: 23523964     Source Type: Journal    
DOI: 10.1016/j.ebiom.2015.10.008     Document Type: Note

References (9)

1. Dye C., Glaziou P., Floyd K., Raviglione M. Prospects for tuberculosis elimination. Annu. Rev. Public Health 2013, 34:271-286.
2. Evangelopoulos D., McHugh T.D. Improving the tuberculosis drug development pipeline. Chem. Biol. Drug Des. 2015, (Mar 16). 10.1111/cbdd.12549.
3. Fenner L., Egger M., Bodmer T., Altpeter E., Zwahlen M., Jaton K., Pfyffer G.E., Borrell S., Dubuis O., Bruderer T., Siegrist H.H., Furrer H., Calmy A., Fehr J., Stalder J.M., Ninet B., Böttger E.C., Gagneux S., Swiss HIV Cohort Study and the Swiss Molecular Epidemiology of Tuberculosis Study Group Effect of mutation and genetic background on drug resistance in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2012, 56:3047-3053.
4. Noor K.M., Shephard L., Bastian I. Molecular diagnostics for tuberculosis. Pathology 2015, 47:250-256.
5. Salamon H., Yamaguchi K.D., Cirillo D.M., Miotto P., Schito M., Posey J., Starks A.M., Niemann S., Alland D., Hanna D., Aviles E., Perkins M.D., Dolinger D.L. Integration of published information into a resistance-associated mutation database for Mycobacterium tuberculosis. J. Infect. Dis. Suppl. 2015, 2:S50-S57.
6. Sotgiu G., Migliori G.B. Facing multi-drug resistant tuberculosis. Pulm Pharmacol Ther. 2015, 32:144-148.
7. Starks A.M., Avilés E., Cirillo D.M., Denkinger C.M., Dolinger D.L., Emerson C.E., Gallarda J., Hanna D., Kim P.S., Liwski R., Miotto P., Schito M., Matteo Z.M. Collaborative effort for a centralized worldwide tuberculosis relational sequencing data platform. Clin. Infect. Dis. 2015, 61(Suppl. 3):S141-S146.
8. Walker T.M., Kohl T.A., Omar S.V., Hedge J., Del Ojo Elias C., Bradley P., Iqbal Z., Feuerriegel S., Niehaus K.E., Wilson D.J., Clifton D.A., Kapatai G., Ip C.L., Bowden R., Drobniewski F.A., Allix-Béguec C., Gaudin C., Parkhill J., Diel R., Supply P., Crook D.W., Smith E.G., Walker A.S., Ismail N., Niemann S., Peto T.E., Modernizing Medical Microbiology (MMM) Informatics Group Whole-genome sequencing for prediction of Mycobacterium tuberculosis drug susceptibility and resistance: a retrospective cohort study. Lancet Infect. Dis. 2015, 15:1193-1202.
9. Wells W.A., Boehme C.C., Cobelens F.G., Daniels C., Dowdy D., Gardiner E., Gheuens J., Kim P., Kimerling M.E., Kreiswirth B., Lienhardt C., Mdluli K., Pai M., Perkins M.D., Peter T., Zignol M., Zumla A., Schito M. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect. Dis. 2013, 13(5):449-458.